News | February 24, 2022
Cadila Healthcare is now Zydus Lifesciences
Zydus unveils its ‘innovation and care’ centric corporate brand identity
Zydus unveils its ‘innovation and care’ centric corporate brand identity
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
Subscribe To Our Newsletter & Stay Updated
